Y2Solution Reports Q1 Sales of 86.7 Billion Won and Operating Profit of 1 Billion Won, "Business Scale More Than Doubled Year-on-Year"

Y2Solution announced on May 14 that it entered a full-fledged growth trajectory in the first quarter of this year, having more than doubled its business size compared to the same period last year.

According to its disclosure, Y2Solution recorded consolidated sales of 86.7 billion won in the first quarter of this year, up 128% year-on-year. Operating profit during the same period turned positive quarter-on-quarter, reaching 1 billion won. The stabilization of its existing business and rapid growth in its bioenergy segment drove the improvement in results.

The bioenergy business has established itself as a new growth axis by securing distribution networks amid strengthened eco-friendly policies in Europe and rising demand for renewable raw materials. This division has contributed to enhancing the profit structure not only by expanding its scale but also by generating stable cash flows.

Y2Solution has strengthened its mid- to long-term growth foundation by adding the bioenergy business to the stable profit structure of its existing power supply unit (PSU) business. Based on this, the company plans to expand investments in future growth businesses such as robotics and bio.

The robotics division is developing an ultra-low-profile autonomous mobile robot (AMR) platform. Recently, through collaboration with Wizgen, Y2Solution has been advancing next-generation robot drive system technology based on axial flux permanent magnet (AFPM) motors. The company aims to unveil an ultra-low-profile AMR prototype within the year.

In the bio segment, clinical development is accelerating, led by LUXA, a company developing a cell therapy for dry age-related macular degeneration. LUXA confirmed the potential for vision improvement in early clinical trials and was designated as a regenerative medicine advanced therapy (RMAT) by the U.S. Food and Drug Administration (FDA). The company plans to successfully complete Phase 1/2a clinical trials within the year and secure topline data to lay the groundwork for its commercialization strategy.

A Y2Solution representative stated, "After building the foundation for new businesses and restructuring last year, we saw those efforts reflected in our first-quarter results this year," adding, "We plan to continuously expand our investment in future growth engines, based on the stable profit structure established around the bioenergy business."

This content was produced with the assistance of AI translation services.